|Positive WB detected in||Calyculin A treated HEK-293T cells|
|Western Blot (WB)||WB : 1:1000-1:8000|
|Sample-dependent, check data in validation data gallery|
28805-1-AP targets Phospho-Chk1 (Ser296) in WB, ELISA applications and shows reactivity with Human, mouse, rat samples.
|Tested Reactivity||Human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Full Name||CHK1 checkpoint homolog (S. pombe)|
|Calculated molecular weight||54 kDa|
|Observed molecular weight||55 kDa|
|GenBank accession number||BC004202|
|Gene ID (NCBI)||1111|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
In response to DNA damage, mammalian cells prevent cell cycle progression through the control of critical cell cycle regulators. CHK1 (synonym: CHEK1), a homolog of the Schizosaccharomyces pombe Chk1 protein kinase, is required for the DNA damage checkpoint. Human Chk1 protein is modified in response to DNA damage. In vitro Chk1 binds to and phosphorylate the dual-specificity protein phosphatases Cdc25A, Cdc25B, and Cdc25C, which control cell cycle transitions by dephosphorylating cyclin-dependent kinases. CHK1 can be autophosphorylated (PMID:22941630) and ubiquitinated (PMID:19276361). Activation of Chk1 involves phosphorylation at Ser317 and Ser345 by ATM/ATR, followed by autophosphorylation of Ser296. Activation occurs in response to blocked DNA replication and certain forms of genotoxic stress.
eIF3a-PPP2R5A-mediated ATM/ATR dephosphorylation is essential for irinotecan-induced DNA damage response.
Adv Sci (Weinh)
Transferrin Receptor-Mediated Iron Uptake Promotes Colon Tumorigenesis
Research (Wash D C)
Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer
SIRT3-dependent mitochondrial redox homeostasis mitigates CHK1 inhibition combined with gemcitabine treatment induced cardiotoxicity in hiPSC-CMs and mice